Literature DB >> 19913962

Intensify, resuscitate or palliate: decision making in the critically ill patient with haematological malignancy.

Quentin A Hill1.   

Abstract

The survival prospects of critically ill patients with haematological malignancy (HM) are reviewed, as are the variables which might influence decisions about the limitation of life sustaining therapies (LLST). Approximately 40% of patients with HM admitted to ICU survive to hospital discharge and a broad admission policy is warranted. Short term survival is predicted by the severity of the underlying physiological disturbance rather than cancer specific characteristics, although the prognostic importance of neutropenia and prior stem cell transplantation remains to be clarified. Survival to hospital discharge in cancer patients following cardio-pulmonary resuscitation (CPR) is only 6-8%. Poor performance status and progressive deterioration despite ICU support appear to predict worse outcome. Patients should be provided with realistic information in order to make an informed decision about CPR. Decisions about LLST must be individualised. Consideration should be given to the patient's wishes and prognosis, the immediate clinical circumstances and their potential reversibility. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19913962     DOI: 10.1016/j.blre.2009.10.002

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  19 in total

1.  Dying of hematologic patients--treatment characteristics in a German University Hospital.

Authors:  Patrick Brück; Malgorzata Pierzchlewska; Marta Kaluzna-Oleksy; Maria Elizabeth Ramos Lopez; Mathias Rummel; Dieter Hoelzer; Angelika Böhme
Journal:  Support Care Cancer       Date:  2012-03-13       Impact factor: 3.603

2.  Supporting respiratory function in the immunocompromised critically ill patient: new perspectives for an old paradigm.

Authors:  Lorenzo Ball; Paolo Pelosi
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

Review 3.  Palliative care during and following allogeneic hematopoietic stem cell transplantation.

Authors:  Sandra A Mitchell
Journal:  Curr Opin Support Palliat Care       Date:  2018-03       Impact factor: 2.302

4.  Has survival increased in cancer patients admitted to the ICU? Yes.

Authors:  Djamel Mokart; Stephen M Pastores; Michael Darmon
Journal:  Intensive Care Med       Date:  2014-08-27       Impact factor: 17.440

5.  Prognostic factors in critically ill patients with hematological malignancy admitted to the general intensive care unit: a single-center experience in Japan.

Authors:  Hiromasa Irie; Takanao Otake; Keiko Kawai; Masaaki Hino; Ayano Namazu; Yasutaka Shinjo; Shigeki Yamashita
Journal:  J Anesth       Date:  2017-08-01       Impact factor: 2.078

Review 6.  Palliative Care in Patients with Leukemia: When and How?

Authors:  Marieberta Vidal; David Hui; Eduardo Bruera
Journal:  Curr Oncol Rep       Date:  2018-11-13       Impact factor: 5.075

7.  Advance directives in an oncologic intensive care unit: a contemporary analysis of their frequency, type, and impact.

Authors:  Neil A Halpern; Stephen M Pastores; Joanne F Chou; Sanjay Chawla; Howard T Thaler
Journal:  J Palliat Med       Date:  2011-03-18       Impact factor: 2.947

8.  Clinical characteristics and outcomes of patients with acute myelogenous leukemia admitted to intensive care: a case-control study.

Authors:  Amanda L Roze des Ordons; Kris Chan; Imran Mirza; Derek R Townsend; Sean M Bagshaw
Journal:  BMC Cancer       Date:  2010-09-28       Impact factor: 4.430

Review 9.  Critically ill allogeneic hematopoietic stem cell transplantation patients in the intensive care unit: reappraisal of actual prognosis.

Authors:  C Saillard; D Blaise; D Mokart
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

10.  [The palliative patient as an emergency patient: A model for decision making in life-threatening situations using 4 case reports].

Authors:  S Trzeczak
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-09-18       Impact factor: 0.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.